insights_auto
Outlook: 40.9% bullish·18.2% bearish
Go to analysischevron_right
BNTX:NASDAQ
BioNTech SE - ADR
$95.90
arrow_downward
-2.79%(-2.76) 1D
Sep 18, 11:38:31 AM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$98.81
High
$99.25
Low
$95.71
Mkt. cap
24.09B
Avg. vol.
1.45M
Volume
354.68K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.70
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
Open
$98.81
High
$99.25
Low
$95.71
Mkt. cap
24.09B
Avg. vol.
1.45M
Volume
354.68K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.70
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
AD HOC NEWS
·
5 hours ago
BioNTech stock gains on fresh lung cancer data
The Motley Fool
·
6 hours ago
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried?
Simply Wall Street
·
11 hours ago
Did Survival Trial Win Just Shift BioNTech (BNTX) Investment Narrative?
Kalkine Media
·
1 day ago
BioNTech CEO Sahin Ugur Sells 49,000 Shares, Retains 553,209 Shares Post-Transaction
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR